

Special Issue

Radionuclide-Based Theranostics

Message from the Guest Editors

Respected Colleagues, The theranostics paradigm consists of the possibility of labeling a molecular targeting vector (e.g., peptides or antibodies) either with diagnostic (e.g., positron or gamma-emitters) or therapeutic radionuclides (e.g., alfa, beta-emitters, or auger electron-emitters) paving the way for personalizing cancer treatment, with the possibility of using the same targeting agent for diagnostics, staging, monitoring of treatment response, and therapy. In recent years, the field of cancer theranostics has evolved considerably due to the definition of suitable biological targets and targeting strategies (e.g., SSTR- and PSMA-based concepts). We hereby would like to invite you to contribute to this Special Issue. Review or original research articles highlighting current progress in the development of potential targeting agents and the different aspects of theranostics will form the basis of this Special Issue on “Radionuclide-Based Theranostics”. We look forward to your contributions.

Guest Editors

Dr. Mohamed Altai

Division of Oncology and Pathology, Department of Clinical Sciences, Kamprad Laboratory, Lund University, 22243 Lund, Sweden

Dr. Joanna Strand

Division of Oncology and Pathology, Department of Clinical Sciences, Kamprad Laboratory, Lund University, 22243 Lund, Sweden

Deadline for manuscript submissions

closed (20 April 2022)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/93429

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](http://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](http://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).